Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27795574 | 0.90 | ALDH1A1 (0.45) | ALDH1A1RECQLGAAKCNA3PDK2 | |
| SCHEMBL5668019 | 0.89 | ALDH1A1 (0.46) | ALDH1A1RECQLGAACYP3A4SMN1; SMN2 | |
| SCHEMBL28277418 | 0.89 | ALDH1A1 (0.44) | ALDH1A1RECQLKCNA3PDK2 | |
| SCHEMBL5704638 | 0.87 | KCNA3 (0.42) | ALDH1A1RECQLKCNA3SMN1; SMN2TAAR1 | |
| SCHEMBL27487980 | 0.87 | ALDH1A1 (0.42) | ALDH1A1RECQLKCNA3PDK2 | |
| SCHEMBL920448 | 0.84 | ALDH1A1 (0.38) | ALDH1A1RECQLKCNA3TAAR1CA12 | |
| SCHEMBL20603111 | 0.83 | — | — | |
| SCHEMBL129009 | 0.80 | KMT2A (0.42) | KCNA3SMN1; SMN2CA12CA1CA9 | |
| SCHEMBL16861350 | 0.80 | HDAC3 (0.42) | ALDH1A1RECQLKCNA3TAAR1 | |
| SCHEMBL920753 | 0.80 | KCNA3 (0.37) | ALDH1A1RECQLKCNA3TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111601810-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-08-28 | — | — | CN | claimed |
| US-10675355-B2 | VAR2CSA-drug conjugates | VAR2 PHARMACEUTICALS APS (DK) | 2020-06-09 | — | — | US | claimed |
| US-20180117163-A9 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2018-05-03 | — | — | US | claimed |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-08-31 | — | — | US | claimed |
| US-20170079954-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2017-03-23 | — | — | US | claimed |
| US-9540351-B2 | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | claimed |
| EP-3087091-A1 | VAR2CSA-DRUG CONJUGATES | Zymeworks Inc. (CA) | 2016-11-02 | — | — | EP | claimed |
| EP-3046918-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2016-07-27 | — | — | EP | claimed |
| US-9382237-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | claimed |
| US-9365556-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-20130303492-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2013-11-14 | — | — | US | claimed |
| US-20130274227-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | US | claimed |
| WO-2013138613-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | WO | claimed |
| WO-2013138617-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | WO | claimed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | claimed |
| EP-1194417-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AG (DE) | 2002-04-10 | — | — | EP | claimed |
| EP-1127051-A2 | TRICYCLIC PYRAZOLE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-29 | — | — | EP | claimed |
| WO-2000078733-A1 | PHENOXY FLUOROPYRIMIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-28 | — | — | WO | claimed |
| WO-2000027822-A2 | TRICYCLIC PYRAZOLE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-18 | — | — | WO | claimed |
| EP-0536896-B1 | Imidazolidyl macrolides having immunosuppressive activity | MERCK & CO INC (US) | 1997-12-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | ALDH1A1 2400/4885RECQL 4179/4885GAA 1650/4885 |
| US-20130274227-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, MAP3K1 | ALDH1A1 2629/4885RECQL 1327/4885GAA 1697/4885 |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | VARS1, GUSB, VAV1 | ALDH1A1 527/4885RECQL 4426/4885GAA 108/4885 |
| US-20170079954-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | GRK3, DMPK, PRKAG3 | ALDH1A1 1676/4885RECQL 1141/4885GAA 1521/4885 |
| US-10675355-B2 | VAR2CSA-drug conjugates | VARS1, GUSB, VAV1 | ALDH1A1 527/4885RECQL 4426/4885GAA 108/4885 |
| US-20180117163-A9 | VAR2CSA-DRUG CONJUGATES | VARS1, GUSB, VAV1 | ALDH1A1 527/4885RECQL 4426/4885GAA 108/4885 |
| US-20130303492-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, MAP3K1 | ALDH1A1 2629/4885RECQL 1327/4885GAA 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.